Skip to main content
NCBI home page
Thorax logoLink to Thorax
. 2005 Sep;60(9):730–734. doi: 10.1136/thx.2004.039180

Moderate dose inhaled corticosteroids plus salmeterol versus higher doses of inhaled corticosteroids in symptomatic asthma

M Masoli 1, M Weatherall 1, S Holt 1, R Beasley 1
PMCID: PMC1747519  PMID: 16135679

Abstract

Background: There is uncertainty as to the dose of inhaled corticosteroids (ICS) at which to start concomitant long acting ß agonist (LABA) treatment in patients with asthma not adequately controlled by ICS alone.

Methods: A meta-analysis was carried out of randomised, double blind clinical trials that compared the efficacy of adding salmeterol to moderate doses of ICS (fluticasone propionate 200 µg/day or equivalent) with increasing the ICS dose by at least twofold in symptomatic adult patients with asthma. The main outcome measures were the number of subjects withdrawn from the study due to asthma and the number of subjects with at least one moderate or severe exacerbation.

Results: Twelve studies with a total of 4576 subjects met the inclusion criteria for the analyses. The number of subjects withdrawn due to asthma and with at least one moderate or severe exacerbation was higher in the high dose ICS group (odds ratios 1.58, 95% CI 1.12 to 2.24 and 1.35, 95% CI 1.10 to 1.66, respectively). For the secondary outcome variables (forced expiratory volume in 1 second, morning and evening peak expiratory flow, and daytime ß agonist use) there was significantly greater benefit in the salmeterol group.

Conclusions: This meta-analysis shows that the addition of salmeterol to moderate doses of ICS (fluticasone 200 µg/day or equivalent) in patients with asthma symptomatic at that dose results in significantly greater clinical benefit than increasing the dose of ICS by twofold or more.

Full Text

The Full Text of this article is available as a PDF (79.5 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Baraniuk J., Murray J. J., Nathan R. A., Berger W. E., Johnson M., Edwards L. D., Srebro S., Rickard K. A. Fluticasone alone or in combination with salmeterol vs triamcinolone in asthma. Chest. 1999 Sep;116(3):625–632. doi: 10.1378/chest.116.3.625. [DOI] [PubMed] [Google Scholar]
  2. Bouros D., Bachlitzanakis N., Kottakis J., Pfister P., Polychronopoulos V., Papadakis E., Constantopoulos S., Froudarakis M., Sichletidis L., Siafakas N. Formoterol and beclomethasone versus higher dose beclomethasone as maintenance therapy in adult asthma. Eur Respir J. 1999 Sep;14(3):627–632. doi: 10.1034/j.1399-3003.1999.14c24.x. [DOI] [PubMed] [Google Scholar]
  3. Busse William, Koenig Steven M., Oppenheimer John, Sahn Steven A., Yancey Steven W., Reilly Donna, Edwards Lisa D., Dorinsky Paul M. Steroid-sparing effects of fluticasone propionate 100 microg and salmeterol 50 microg administered twice daily in a single product in patients previously controlled with fluticasone propionate 250 microg administered twice daily. J Allergy Clin Immunol. 2003 Jan;111(1):57–65. doi: 10.1067/mai.2003.38. [DOI] [PubMed] [Google Scholar]
  4. Condemi J. J., Goldstein S., Kalberg C., Yancey S., Emmett A., Rickard K. The addition of salmeterol to fluticasone propionate versus increasing the dose of fluticasone propionate in patients with persistent asthma. Salmeterol Study Group. Ann Allergy Asthma Immunol. 1999 Apr;82(4):383–389. doi: 10.1016/s1081-1206(10)63288-7. [DOI] [PubMed] [Google Scholar]
  5. Greening A. P., Ind P. W., Northfield M., Shaw G. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Allen & Hanburys Limited UK Study Group. Lancet. 1994 Jul 23;344(8917):219–224. doi: 10.1016/s0140-6736(94)92996-3. [DOI] [PubMed] [Google Scholar]
  6. Higgins Julian P. T., Thompson Simon G. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002 Jun 15;21(11):1539–1558. doi: 10.1002/sim.1186. [DOI] [PubMed] [Google Scholar]
  7. Holt S., Suder A., Weatherall M., Cheng S., Shirtcliffe P., Beasley R. Dose-response relation of inhaled fluticasone propionate in adolescents and adults with asthma: meta-analysis. BMJ. 2001 Aug 4;323(7307):253–256. doi: 10.1136/bmj.323.7307.253. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Jadad A. R., Moore R. A., Carroll D., Jenkinson C., Reynolds D. J., Gavaghan D. J., McQuay H. J. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996 Feb;17(1):1–12. doi: 10.1016/0197-2456(95)00134-4. [DOI] [PubMed] [Google Scholar]
  9. Kelsen S. G., Church N. L., Gillman S. A., Lanier B. Q., Emmett A. H., Rickard K. A., Anderson W. H. Salmeterol added to inhaled corticosteroid therapy is superior to doubling the dose of inhaled corticosteroids: a randomized clinical trial. J Asthma. 1999 Dec;36(8):703–715. doi: 10.3109/02770909909055422. [DOI] [PubMed] [Google Scholar]
  10. Lalloo Umesh G., Malolepszy Jóseph, Kozma Dezsó, Krofta Kamil, Ankerst Jaro, Johansen Bjørn, Thomson Neil C. Budesonide and formoterol in a single inhaler improves asthma control compared with increasing the dose of corticosteroid in adults with mild-to-moderate asthma. Chest. 2003 May;123(5):1480–1487. doi: 10.1378/chest.123.5.1480. [DOI] [PubMed] [Google Scholar]
  11. Masoli M., Weatherall M., Holt S., Beasley R. Clinical dose-response relationship of fluticasone propionate in adults with asthma. Thorax. 2004 Jan;59(1):16–20. [PMC free article] [PubMed] [Google Scholar]
  12. Murray J. J., Church N. L., Anderson W. H., Bernstein D. I., Wenzel S. E., Emmett A., Rickard K. A. Concurrent use of salmeterol with inhaled corticosteroids is more effective than inhaled corticosteroid dose increases. Allergy Asthma Proc. 1999 May-Jun;20(3):173–180. doi: 10.2500/108854199778553028. [DOI] [PubMed] [Google Scholar]
  13. Nelson H. S., Busse W. W., deBoisblanc B. P., Berger W. E., Noonan M. J., Webb D. R., Wolford J. P., Mahajan P. S., Hamedani A. G., Shah T. Fluticasone propionate powder: oral corticosteroid-sparing effect and improved lung function and quality of life in patients with severe chronic asthma. J Allergy Clin Immunol. 1999 Feb;103(2 Pt 1):267–275. doi: 10.1016/s0091-6749(99)70501-4. [DOI] [PubMed] [Google Scholar]
  14. Nightingale Julia A., Rogers Duncan F., Barnes Peter J. Comparison of the effects of salmeterol and formoterol in patients with severe asthma. Chest. 2002 May;121(5):1401–1406. doi: 10.1378/chest.121.5.1401. [DOI] [PubMed] [Google Scholar]
  15. Noonan M., Chervinsky P., Busse W. W., Weisberg S. C., Pinnas J., de Boisblanc B. P., Boltansky H., Pearlman D., Repsher L., Kellerman D. Fluticasone propionate reduces oral prednisone use while it improves asthma control and quality of life. Am J Respir Crit Care Med. 1995 Nov;152(5 Pt 1):1467–1473. doi: 10.1164/ajrccm.152.5.7582278. [DOI] [PubMed] [Google Scholar]
  16. O'Byrne P. M., Barnes P. J., Rodriguez-Roisin R., Runnerstrom E., Sandstrom T., Svensson K., Tattersfield A. Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial. Am J Respir Crit Care Med. 2001 Oct 15;164(8 Pt 1):1392–1397. doi: 10.1164/ajrccm.164.8.2104102. [DOI] [PubMed] [Google Scholar]
  17. Pauwels R. A., Löfdahl C. G., Postma D. S., Tattersfield A. E., O'Byrne P., Barnes P. J., Ullman A. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med. 1997 Nov 13;337(20):1405–1411. doi: 10.1056/NEJM199711133372001. [DOI] [PubMed] [Google Scholar]
  18. Shrewsbury S., Pyke S., Britton M. Meta-analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma (MIASMA). BMJ. 2000 May 20;320(7246):1368–1373. doi: 10.1136/bmj.320.7246.1368. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Szefler Stanley J., Martin Richard J., King Tonya Sharp, Boushey Homer A., Cherniack Reuben M., Chinchilli Vernon M., Craig Timothy J., Dolovich Myrna, Drazen Jeffrey M., Fagan Joanne K. Significant variability in response to inhaled corticosteroids for persistent asthma. J Allergy Clin Immunol. 2002 Mar;109(3):410–418. doi: 10.1067/mai.2002.122635. [DOI] [PubMed] [Google Scholar]
  20. Vermetten F. A., Boermans A. J., Luiten W. D., Mulder P. G., Vermue N. A. Comparison of salmeterol with beclomethasone in adult patients with mild persistent asthma who are already on low-dose inhaled steroids. J Asthma. 1999;36(1):97–106. doi: 10.3109/02770909909065153. [DOI] [PubMed] [Google Scholar]
  21. Vervloet D., Ekström T., Pela R., Duce Gracia F., Kopp C., Silvert B. D., Quebe-Fehling E., Della Cioppa G., Di Benedetto G. A 6-month comparison between formoterol and salmeterol in patients with reversible obstructive airways disease. Respir Med. 1998 Jun;92(6):836–842. doi: 10.1016/s0954-6111(98)90385-7. [DOI] [PubMed] [Google Scholar]
  22. van Noord J. A., Schreurs A. J., Mol S. J., Mulder P. G. Addition of salmeterol versus doubling the dose of fluticasone propionate in patients with mild to moderate asthma. Thorax. 1999 Mar;54(3):207–212. doi: 10.1136/thx.54.3.207. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES